chronic
obstruct
pulmonari
diseas
copd
defin
common
prevent
treatabl
diseas
character
persist
respiratori
symptom
airflow
limit
caus
exposur
noxiou
particl
gase
progress
airflow
limit
attribut
chronic
inflamm
lead
small
airway
obstruct
parenchym
inflamm
exacerb
airflow
limit
copd
associ
abnorm
inflammatori
respons
progress
airflow
limit
associ
increas
accumul
mucu
exud
lumen
infiltr
small
airway
wall
inflammatori
cell
varieti
inflammatori
cell
present
airway
patient
copd
neutrophil
macrophag
eosinophil
mast
cell
lymphocyt
shown
play
import
role
inflammatori
process
copd
neutrophil
one
major
inflammatori
cell
type
copd
increas
number
neutrophil
sputum
found
correl
rapid
declin
patient
forc
expiratori
volum
one
second
fev
period
observ
stabl
copd
patient
fev
show
signific
invers
correl
number
neutrophil
induc
sputum
subepithelium
bronchial
biopsi
suggest
neutrophil
inflamm
airway
may
play
import
role
pathogenesi
copd
macrophag
activ
cigarett
smoke
releas
inflammatori
mediat
matrix
metalloproteas
mmp
number
alveolar
macrophag
correl
extent
emphysema
format
sever
airway
obstruct
mmp
zn
depend
proteas
ca
depend
proteas
degrad
broad
rang
connect
tissu
protein
involv
remodel
damag
tissu
increas
activ
collagenas
gelatinas
detect
induc
sputum
patient
copd
activ
correl
degre
airflow
limit
anim
model
knockout
mice
defici
block
increas
macrophag
lung
develop
emphysema
respons
longterm
exposur
cigarett
smoke
addit
mediat
smokeinduc
inflamm
releas
tumor
necrosi
factor
macrophag
subsequ
endotheli
activ
neutrophil
influx
proteolyt
matrix
breakdown
caus
neutrophilderiv
proteas
role
eosinophil
copd
mechan
eosinophil
influx
airway
remain
clarifi
hogg
et
al
report
eosinophil
exist
small
airway
variou
sever
copd
prospect
clinic
observ
nearli
one
third
copd
patient
sputum
eosinophilia
number
eosinophil
significantli
correl
level
exhal
nitric
oxid
degre
eosinophil
inflamm
relat
earli
chang
lung
function
smoke
habit
higher
count
eosinophil
induc
sputum
associ
higher
packyear
lower
peak
expiratori
flow
valu
retrospect
analysi
fev
revers
weakli
correl
sputum
eosinophil
level
patient
fev
l
increment
higher
sputum
eosinophil
level
wherea
level
differ
dichotom
fev
increment
l
respons
corticosteroid
copd
patient
better
subset
patient
present
eosinophil
higher
level
eosinophil
cation
protein
suggest
corticosteroid
may
effect
especi
patient
copd
eosinophil
airway
inflamm
addit
report
inhal
fluticason
significantli
suppress
number
eosinophil
airway
copd
suppress
eosinophil
inflamm
associ
improv
lung
function
brightl
et
al
also
report
improv
fev
associ
reduct
sputum
eosinophil
count
copd
sputum
eosinophilia
increas
lymphocyt
shown
central
peripher
airway
lung
parenchyma
copd
increas
number
lymphocyt
subepithelium
correl
sever
airflow
limit
increas
cytotox
activ
cell
observ
induc
sputum
patient
copd
compar
smoker
without
copd
healthi
subject
express
perforin
secret
molecul
caus
cytolysi
also
high
howev
one
vitro
studi
demonstr
cytolyt
activ
cell
alveolar
epitheli
cell
perforinindepend
attribut
entir
express
cell
howev
contribut
cell
ratio
cell
pathogenesi
copd
well
cell
recruit
airway
clear
acut
exacerb
associ
increas
inflam
matori
burden
lead
worsen
respiratori
symptom
includ
dyspnea
sputum
product
eclips
studi
exacerb
rate
number
yrpatient
patient
global
initi
obstruct
lung
diseas
gold
stage
respect
first
year
followup
exacerb
rate
significantli
associ
postbronchodil
fev
impair
health
statu
histori
reflux
heartburn
white
blood
cell
count
prior
histori
exacerb
addit
acut
exacerb
copd
found
independ
factor
mortal
suggest
exacerb
higher
mortal
subgroup
analysi
inhal
steroid
obstruct
lung
diseas
europ
isold
studi
patient
without
inhal
corticosteroid
treatment
exacerb
first
year
followup
threeyear
studi
period
patient
respect
exacerb
retrospect
observ
studi
copd
patient
gold
classif
group
b
c
acut
exacerb
previou
year
enrol
inflamm
prospect
observ
studi
copd
patient
bacteria
virusassoci
exacerb
respect
common
caus
bacteriaassoci
exacerb
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
major
virus
associ
copd
exacerb
rhinoviru
common
cold
coronaviru
influenza
parainfluenza
papi
et
al
report
patient
infecti
exacerb
bacteria
viru
coinfect
may
longer
hospit
greater
impair
lung
function
compar
noninfecti
exacerb
sputum
neutrophilia
observ
exacerb
associ
diseas
sever
sputum
eosinophilia
observ
virusassoci
exacerb
normal
lower
airway
steril
bacteri
compon
flagella
lipoprotein
lipopolysaccharid
may
initi
inflammatori
reaction
releas
varieti
proinflammatori
mediat
recruit
inflammatori
cell
exampl
protein
staphylococci
recogn
receptor
airway
epithelium
induc
product
import
chemokin
neutrophil
pseudomona
aeruginosa
flagella
activ
airway
epitheli
cell
produc
tolllik
receptor
stabl
copd
patient
sputum
neutrophil
level
higher
healthi
subject
suggest
ongo
neutrophil
inflamm
airway
sputum
level
report
correl
total
bacteri
count
bacteri
load
airway
associ
increas
exacerb
frequenc
rhinoviru
infect
increas
product
granulocytemacrophag
colonystimul
factor
gmcsf
airway
epitheli
cell
product
associ
viral
replic
studi
mice
influenza
viru
infect
result
influx
neutrophil
monocyt
lymphocyt
eosinophil
well
variou
chemokin
cytokin
day
infect
increas
concentr
outdoor
pollut
particul
matter
pm
particul
matter
pm
associ
increas
respiratori
symptom
acut
exacerb
hospit
admiss
copd
patient
inhal
high
concentr
may
correl
acut
epitheli
damag
cultur
human
bronchial
epitheli
cell
expos
could
increas
express
gmcsf
lead
airway
edema
inflamm
fibrosi
anim
model
day
exposur
differ
level
pm
report
increas
incid
hospit
admiss
pneumonia
acut
exacerb
copd
metaanalysi
base
cityspecif
regress
model
shortterm
pm
exposur
associ
increas
risk
copd
hospit
epidemiolog
studi
everi
increas
concentr
risk
hospit
copd
increas
respect
season
variat
temperatur
may
affect
incid
acut
exacerb
copd
tseng
et
al
report
decreas
air
temperatur
associ
increas
exacerb
rate
eventday
cold
temperatur
report
link
bronchoconstrict
fev
decreas
especi
copd
patient
gastroesophag
reflux
contain
gastric
acid
bile
pepsin
gastroesophag
reflux
ger
major
caus
subacut
chronic
cough
questionnairebas
prospect
survey
preval
ger
diseas
gerd
among
stabl
copd
patient
sever
gerd
symptom
associ
frequent
exacerb
copd
hospit
crude
rel
risk
respect
casanova
et
al
report
sever
copd
patient
high
preval
gerd
confirm
esophag
ph
monitor
reflux
symptom
addit
annual
rate
exacerb
copd
twice
high
patient
ger
symptom
compar
without
ger
tuberc
respir
di
wwwetrdorg
symptom
vs
previou
studi
amount
total
bile
acid
induc
sputum
significantli
higher
patient
ger
asthmaassoci
ger
symptom
compar
healthi
control
subject
p
bile
acid
significantli
induc
transform
growth
factor
product
airway
epitheli
cell
turn
enhanc
fibroblast
prolifer
alter
alveolar
epitheli
permeabl
may
contribut
pathogenesi
lung
injuri
airway
epithelium
expos
bile
acid
could
induc
fibrosi
via
product
connect
tissu
growth
factor
essenti
fibrogenesi
function
downstream
mediat
action
fibroblast
major
bile
acid
chenodeoxychol
acid
stimul
alveolar
epitheli
cell
increas
product
cjun
ntermin
kinas
activ
may
enhanc
neutrophil
inflamm
chronic
airway
disord
interven
attenu
gerrel
inflamm
fibrogenesi
chronic
airway
disord
worth
investig
preval
bronchiectasi
copd
vari
accord
copd
sever
prospect
observ
studi
moder
sever
copd
patient
signific
detect
bronchiectasi
highresolut
comput
tomographi
scan
lower
lobe
bronchiectasi
associ
bacteri
colon
quantifi
sputum
sampl
martinezgarcia
et
al
report
preval
bronchiectasi
moder
sever
copd
patient
respect
patient
bronchiectasi
chronic
expector
exacerb
indic
sever
airflow
obstruct
greater
posit
cultur
potenti
pathogen
microorgan
haemophilu
influenza
pseudomona
aeruginosa
common
microorgan
isol
sputum
addit
moderatetosever
copd
patient
bronchiectasi
associ
increas
allcaus
mortal
compar
copd
patient
without
bronchiectasi
eosinophil
airway
inflamm
characterist
featur
atop
asthma
exist
subgroup
copd
bafadhel
et
al
report
case
acut
exacerb
copd
associ
sputum
eosinophilia
previou
studi
copd
patient
sputum
eosinophilia
tend
higher
serum
ige
level
posit
allergen
test
patient
asthmacopd
overlap
syndrom
may
present
respiratori
symptom
wors
lung
function
increas
risk
exacerb
hospit
preval
ratio
respect
compar
patient
copd
alon
hardin
et
al
report
patient
asthma
copd
overlap
syndrom
aco
like
experi
frequent
exacerb
odd
ratio
sever
exacerb
past
year
prospect
random
studi
reduct
eosinophil
airway
inflamm
associ
reduct
sever
exacerb
copd
sputum
eosinophilia
high
blood
eosinophil
count
associ
increas
respons
steroid
copd
patient
accordingli
detect
eosinophil
inflamm
crucial
step
make
precis
treatment
copd
patient
epidemiolog
studi
copd
risk
obstruct
sleep
apnea
osa
assess
questionnair
among
copd
patient
preval
report
moder
sever
copd
confirm
polysomnographi
marin
et
al
show
copd
patient
osa
overlap
syndrom
without
continu
posit
airway
pressur
cpap
treatment
higher
mortal
rate
like
sever
copd
exacerb
lead
hospit
rel
risk
confid
interv
ci
compar
patient
copd
alon
osa
exacerb
airway
inflamm
increas
neutrophil
proport
level
bronchoalveolar
lavag
fluid
sampl
moder
sever
copd
patient
augment
inflamm
curb
treatment
cpap
mechan
osa
exacerb
airway
inflamm
copd
remain
elucid
signific
predictor
factor
associ
increas
risk
acut
exacerb
copd
summar
tabl
longact
bronchodil
longact
muscarin
antagonist
lama
long
act
adrenerg
receptor
agonist
laba
major
pharmacolog
drug
copd
improv
airflow
limit
respiratori
symptom
qualiti
life
well
reduc
exacerb
mechan
longact
bronchodil
reduc
exacerb
either
improv
hyperinfl
target
inflamm
remain
controversi
combin
laba
corticosteroid
reduc
number
macrophag
neutrophil
lymphocyt
bronchial
biopsi
tissu
induc
sputum
patient
copd
report
combin
inhal
salmeterol
fluticason
caus
signific
reduct
induc
sputum
copd
patient
compar
level
receiv
treatment
tiotropium
alon
tiotropium
wwwetrdorg
inhibit
airway
inflamm
remodel
attenu
neutrophil
inflamm
well
associ
mediat
ltb
monocyt
chemoattract
macrophag
inflammatori
protein
mip
anim
model
clinic
studi
odd
ratio
tiotropium
reduc
exacerb
compar
placebo
ci
hospit
ci
indacaterol
formoterol
suppress
neutrophilassoci
mediat
reactiv
oxygen
speci
ltb
elastas
dosedepend
manner
prospect
random
blind
doubledummi
studi
found
tiotropium
superior
indacaterol
term
annual
exacerb
rate
vs
sever
copd
combin
indacaterol
glycopyrronium
significantli
reduc
annual
rate
moder
sever
exacerb
versu
glycopyrronium
alon
suggest
combin
indacaterolglycopyrronium
superior
prevent
moder
sever
exacerb
compar
glycopyrronium
alon
roflumilast
pde
inhibitor
report
significantli
reduc
moder
sever
exacerb
compar
placebo
sever
copd
patient
chronic
bronchiti
frequent
exacerb
phenotyp
pde
inhibitor
associ
reduc
likelihood
copd
exacerb
odd
ratio
ci
pool
analysi
choos
optim
laba
lama
dual
bronchodil
pde
inhibitor
inhal
corticosteroid
specif
combin
differ
drug
copd
patient
variou
sever
phenotyp
challeng
clinic
practic
pneumococc
influenza
vaccin
recommend
patient
copd
prevent
strategi
recent
metaanalysi
show
pneumococc
vaccin
provid
signific
protect
communityacquir
pneumonia
cap
reduc
likelihood
copd
exacerb
contrast
sehatzadeh
report
time
first
episod
cap
due
pneumococcu
unknown
etiolog
significantli
differ
vaccin
control
group
nevertheless
hospit
admiss
rate
median
length
hospit
stay
lower
vaccin
group
statist
signific
influenza
vaccin
found
vaccin
group
fewer
episod
influenzarel
acut
respiratori
ill
sever
mild
moder
sever
copd
fewer
hospit
fewer
requir
mechan
ventil
necessari
promot
conduct
research
ambient
air
pollut
copd
risk
factor
necessari
form
partnership
govern
institut
environment
protect
agenc
epa
academ
institut
investig
detriment
effect
environment
exposur
occup
hazard
well
appli
prevent
strategi
patient
educ
us
epa
recommend
time
intens
outdoor
activ
regul
air
qualiti
index
sinc
respir
report
abl
provid
excel
protect
airborn
particl
aspir
gastroesophag
reflux
trigger
exacerb
copd
enhanc
airway
inflamm
fibrosi
discuss
earlier
among
copd
patient
gerd
use
acid
inhibitori
treatment
regularli
significantli
increas
risk
copd
exacerb
hazard
ratio
hr
compar
treat
regularli
hr
moder
sever
asthma
patient
gerd
nocturn
respiratori
symptom
take
proton
pump
inhibitor
significantli
improv
morn
even
peak
expiratori
flow
take
palcebo
abil
identifi
copd
patient
risk
gerd
gerrel
chronic
cough
essenti
copd
manag
worth
conduct
random
trial
investig
efficaci
antiacid
antireflux
therapi
copd
patient
gerd
whether
treatment
decreas
respiratori
symptom
improv
lung
function
qualiti
life
well
reduc
exacerb
prospect
studi
incid
bacteri
colon
bronchiectasi
high
risk
factor
includ
diagnosi
bronchiectasi
age
year
odd
ratio
fev
predict
presenc
varicos
cystic
bronchiectasi
bacteri
infect
caus
airway
inflamm
subsequ
result
exacerb
copd
patient
bronchiectasi
respiratori
symptom
exacerb
wors
prognosi
azithromycin
mg
taken
daili
year
decreas
frequenc
exacerb
hr
p
improv
qualiti
life
among
copd
patient
clinic
efficaci
hospit
urgent
care
visit
intub
similar
group
advers
reaction
hear
impair
common
azithromycin
group
uzun
et
al
report
azithromycin
mg
taken
time
week
month
result
signific
reduct
exacerb
rate
versu
placebo
hr
among
copd
patient
exacerb
previou
year
small
studi
demonstr
inhal
tobramycin
reduc
inflammatori
impact
pseudomona
aeruginosa
multiresist
pseudomonascolon
patient
sever
copd
treatment
reduct
exacerb
rate
observ
followup
abil
select
patient
choos
appropri
antibiot
decid
durat
treatment
major
concern
treatment
strategi
frequent
exacerb
copd
bacteri
colon
whether
eosinophil
inflamm
copd
attribut
aco
specif
phenotyp
copd
still
controversi
howev
respons
eosinophil
inflamm
treatment
would
import
delin
differ
two
term
earli
detect
characterist
featur
asthma
eosinophil
airway
inflamm
copd
patient
necessari
start
treatment
zanini
et
al
report
copd
patient
bronchial
hyperrespons
bhr
higher
sputum
eosinophil
without
bhr
chang
fev
posit
correl
sputum
eosinophil
patient
bronchial
revers
preval
elev
serum
ige
report
copd
patient
serum
ige
level
associ
copd
sever
sputum
eosinophilia
level
eosinophil
sputum
sampl
significantli
correl
exhal
nitric
oxid
level
eno
eno
blood
eosinophil
antigenspecif
ige
significantli
higher
aco
copd
alon
accord
crosssect
studi
japan
blood
eosinophil
propos
surrog
marker
airway
eosinophilia
stabl
copd
marker
respons
inhal
corticosteroid
copd
patient
blood
eosinophil
treat
inhal
corticosteroidlaba
significantli
fewer
exacerb
treat
lama
rel
risk
rr
inspir
studi
placebo
rr
p
warrant
conduct
prospect
studi
determin
marker
better
predict
corticosteroid
respons
copd
eosinophil
airway
inflamm
wwwetrdorg
cpap
consid
standard
treatment
osa
patient
benefit
cpap
treatment
reduc
airway
inflamm
copd
bare
discuss
cpap
may
reduc
oxid
stress
decreas
plasma
malondialdehyd
osa
significantli
reduc
urinari
norepinephrin
level
blood
pressur
patient
sever
osa
briefli
osa
may
exacerb
airway
inflamm
copd
cpap
optim
choic
revers
inflammatori
process
far
though
airway
inflamm
copd
vari
base
sever
still
gap
inflamm
exacerb
bacteri
viral
infect
air
pollut
gerd
bronchiectasi
bacteri
colon
eosinophil
may
breach
airway
stabil
lead
overwhelm
inflamm
acut
exacerb
applic
antiinflammatori
agent
vaccin
prevent
strategi
air
pollut
earli
detect
gerd
reduct
bacteri
load
bronchiectasi
measur
biomark
predict
respons
corticosteroid
becom
therapeut
goal
minim
risk
acut
exacerb
still
need
evid
clinic
studi
achiev
endpoint
improv
healthrel
qualiti
life
among
copd
patient
potenti
conflict
interest
relev
articl
report
